Interim Recommendation Issued for Moderna COVID-19 Vaccine in Adults
An interim recommendation for the use of the Moderna COVID-19 vaccine has been issued for persons aged 18 years and older in the United States. The source is a recommendation document, not a study report. No study design, phase, sample size, comparator, or follow-up duration is reported.
No specific efficacy or safety data are provided. The main results, primary and secondary outcomes, effect sizes, and absolute numbers are all not reported. Similarly, adverse events, serious adverse events, discontinuations, and tolerability data are not reported.
Key limitations include the absence of underlying study data. The practice relevance is explicitly framed as an interim recommendation. Clinicians should interpret this as a guidance document to be followed while awaiting the publication of formal clinical trial results and safety monitoring data.